Cargando…
Correction to: Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211201/ https://www.ncbi.nlm.nih.gov/pubmed/32253718 http://dx.doi.org/10.1007/s40259-020-00423-0 |
| _version_ | 1783531406509473792 |
|---|---|
| author | Ho, Stephanie L. Niu, Fang Pola, Suresh Velayos, Fernando S. Ning, Xian Hui, Rita L. |
| author_facet | Ho, Stephanie L. Niu, Fang Pola, Suresh Velayos, Fernando S. Ning, Xian Hui, Rita L. |
| author_sort | Ho, Stephanie L. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7211201 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-72112012020-05-13 Correction to: Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study Ho, Stephanie L. Niu, Fang Pola, Suresh Velayos, Fernando S. Ning, Xian Hui, Rita L. BioDrugs Correction Springer International Publishing 2020-04-06 2020 /pmc/articles/PMC7211201/ /pubmed/32253718 http://dx.doi.org/10.1007/s40259-020-00423-0 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
| spellingShingle | Correction Ho, Stephanie L. Niu, Fang Pola, Suresh Velayos, Fernando S. Ning, Xian Hui, Rita L. Correction to: Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study |
| title | Correction to: Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study |
| title_full | Correction to: Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study |
| title_fullStr | Correction to: Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study |
| title_full_unstemmed | Correction to: Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study |
| title_short | Correction to: Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study |
| title_sort | correction to: effectiveness of switching from reference product infliximab to infliximab-dyyb in patients with inflammatory bowel disease in an integrated healthcare system in the united states: a retrospective, propensity score-matched, non-inferiority cohort study |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211201/ https://www.ncbi.nlm.nih.gov/pubmed/32253718 http://dx.doi.org/10.1007/s40259-020-00423-0 |
| work_keys_str_mv | AT hostephaniel correctiontoeffectivenessofswitchingfromreferenceproductinfliximabtoinfliximabdyybinpatientswithinflammatoryboweldiseaseinanintegratedhealthcaresystemintheunitedstatesaretrospectivepropensityscorematchednoninferioritycohortstudy AT niufang correctiontoeffectivenessofswitchingfromreferenceproductinfliximabtoinfliximabdyybinpatientswithinflammatoryboweldiseaseinanintegratedhealthcaresystemintheunitedstatesaretrospectivepropensityscorematchednoninferioritycohortstudy AT polasuresh correctiontoeffectivenessofswitchingfromreferenceproductinfliximabtoinfliximabdyybinpatientswithinflammatoryboweldiseaseinanintegratedhealthcaresystemintheunitedstatesaretrospectivepropensityscorematchednoninferioritycohortstudy AT velayosfernandos correctiontoeffectivenessofswitchingfromreferenceproductinfliximabtoinfliximabdyybinpatientswithinflammatoryboweldiseaseinanintegratedhealthcaresystemintheunitedstatesaretrospectivepropensityscorematchednoninferioritycohortstudy AT ningxian correctiontoeffectivenessofswitchingfromreferenceproductinfliximabtoinfliximabdyybinpatientswithinflammatoryboweldiseaseinanintegratedhealthcaresystemintheunitedstatesaretrospectivepropensityscorematchednoninferioritycohortstudy AT huirital correctiontoeffectivenessofswitchingfromreferenceproductinfliximabtoinfliximabdyybinpatientswithinflammatoryboweldiseaseinanintegratedhealthcaresystemintheunitedstatesaretrospectivepropensityscorematchednoninferioritycohortstudy |